Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. Mar 9, 2024; 13(1): 89026
Published online Mar 9, 2024. doi: 10.5492/wjccm.v13.i1.89026
Published online Mar 9, 2024. doi: 10.5492/wjccm.v13.i1.89026
Systematic review with expert consensus on use of extracorporeal hemoadsorption in septic shock: An Indian perspective
Yatin Mehta, Institute of Critical Care and Anesthesiology, Medanta The Medicity, Gurgaon 122001, Haryana, India
Abdul Samad Ansari, Department of Critical Care, Nanavati Max Super Specialty Hospital, Mumbai 400065, India
Amit Kumar Mandal, Department of Pulmonology, Sleep and Critical Care, Fortis Hospital, Mohali, Punjab, Mohali 160062, Punjab , India
Dipanjan Chatterjee, Department of Cardio-Puimonary Critical Care, Medica Superspecialty Hospital, Kolkata 700099, India
Gauri Shankar Sharma, Department of Critical Care Medicine, Fortis Hospital, New Delhi 110070, India
Prachee Sathe, Department of Critical Care Medicine, D.Y. Patil Medical College, Sant Tukaram Nagar, Pimpri Colony, Pimpri-Chinchwad,, Pune 411018, India
Purvesh V Umraniya, Department of Critical Care Medicine, Bhailal Amin General Hospital, Vadodara 390003, Gujarat, India
Rajib Paul, Department of Internal Medicine, Apollo Hospitals, Jubilee Hills, Hyderabad 500 033, India
Sachin Gupta, Department of Anaesthesiology, Narayana Superspeciality Hospital, Gurugram 122002, India
Vinod Singh, Department of Critical Care Medicine, Institute of Critical Care Medicine, Hospital Name - Sir Ganga Ram Hospital, New Delhi 110001, India
Yogendra Pal Singh, Department of Critical Care Medicine, Max Super Speciality Hospital, Delhi 110092, India
Author contributions: Mehta Y, Ansari A, Mandal AK, Chatterjee D, Sharma GS, Sathe P, Umraniya PV, Paul R, Gupta S, Singh VK, and Singh YP contributed to conceptualization/ideation, data analysis; contributed to writing – original draft, writing – review & editing; all the authors have equally contributed towards conceptualization/ideation, data analysis, manuscript review and final approval; all authors have read and agreed to the published version of the manuscript.
Conflict-of-interest statement: All the authors declare no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yatin Mehta, DNB, MD, Chairman, Doctor, Institute of Critical Care and Anesthesiology, Medanta The Medicity, Gurgaon 122001, Haryana, India. yatinmehta@hotmail.com
Received: October 18, 2023
Peer-review started: October 18, 2023
First decision: November 23, 2023
Revised: December 5, 2023
Accepted: January 17, 2024
Article in press: January 17, 2024
Published online: March 9, 2024
Processing time: 138 Days and 13.7 Hours
Peer-review started: October 18, 2023
First decision: November 23, 2023
Revised: December 5, 2023
Accepted: January 17, 2024
Article in press: January 17, 2024
Published online: March 9, 2024
Processing time: 138 Days and 13.7 Hours
Core Tip
Core Tip: This evidence-based expert consensus statement gives information/clarity on the key areas of knowledge gaps of CytoSorb® therapy: need for adjuvant therapy, initiation timeline, need for Interleukin -6 levels, duration of therapy, change of adsorbers, safety, prerequisite condition, efficacy endpoints, and (therapy) management flowchart. This expert consensus statements provides general physicians, emergency care physicians, anaesthetist, and intensivists with current information regarding the use of CytoSorb® haemoadsorption as an adjuvant treatment in patients with refractory septic shock.